Mdr-1 C3435t Polymorphism May Affect Blood Pressure In Resistant Hypertensive Patients Independently Of Its Effects On Aldosterone Release

dc.creatorLacchini R.
dc.creatorFigueiredo V.N.
dc.creatorDemacq C.
dc.creatorCoeli-Lacchini F.B.
dc.creatorMartins L.C.
dc.creatorYugar-Toledo J.
dc.creatorCoca A.
dc.creatorTanus-Santos J.E.
dc.creatorMoreno Jr. H.
dc.date2014
dc.date2015-06-25T17:52:16Z
dc.date2015-11-26T14:15:41Z
dc.date2015-06-25T17:52:16Z
dc.date2015-11-26T14:15:41Z
dc.date.accessioned2018-03-28T21:16:37Z
dc.date.available2018-03-28T21:16:37Z
dc.identifier
dc.identifierJraas - Journal Of The Renin-angiotensin-aldosterone System. Sage Publications Ltd, v. 15, n. 2, p. 170 - 176, 2014.
dc.identifier14703203
dc.identifier10.1177/1470320312466124
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84902137965&partnerID=40&md5=0aa4d551e7beb628cfb466cb8602062b
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/86255
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/86255
dc.identifier2-s2.0-84902137965
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1242863
dc.descriptionAldosterone increases plasma volume and may be involved with resistant hypertension. P-glycoprotein is a transporter involved in the distribution and disposition of aldosterone, and is encoded by the MDR-1 gene. MDR-1 has functional polymorphisms that may affect P-glycoprotein expression. We hypothesized that the C3435T polymorphism in MDR-1 could be associated with resistant hypertension and with changes in hypertension-related parameters. We studied 105 healthy volunteers, 137 hypertensive patients responsive to treatment, and 83 resistant hypertensive patients. While we found no association of C3435T genotypes with resistance to treatment (p = 0.31), C allele was associated with hypertension (p = 0.03). Furthermore, the CC genotype was associated with higher systolic blood pressure (p < 0.01 for both daytime and nighttime, respectively) and diastolic blood pressure (p < 0.01 for both daytime and nighttime, respectively). This effect was probably independent of aldosterone, as we found no differences in aldosterone plasma levels, nor in pulse wave velocity (PVW) between the genotypes groups (p = 0.77 and p = 0.48, respectively). Our results show an association of C3435T with hypertension and with blood pressure levels in resistant hypertensive subjects. © 2014 The Author(s).
dc.description15
dc.description2
dc.description170
dc.description176
dc.descriptionCutler, J.A., High blood pressure and end-organ damage (1996) J Hypertens Suppl, 14, pp. S3-S6
dc.descriptionDe Souza, W.A., Sabha, M., De Faveri, Favero, F., Intensive monitoring of adherence to treatment helps to identify "true" resistant hypertension (2009) J Clin Hypertens (Greenwich), 11, pp. 183-191
dc.descriptionCalhoun, D.A., Jones, D., Textor, S., Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research (2008) Hypertension, 51, pp. 1403-1419
dc.descriptionChobanian, A.V., Bakris, G.L., Black, H.R., The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report (2003) JAMA, 289, pp. 2560-2572
dc.descriptionCalhoun, D.A., Jones, D., Textor, S., Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research (2008) Circulation, 117, pp. e510-e526
dc.descriptionCuspidi, C., Vaccarella, A., Negri, F., Resistant hypertension and left ventricular hypertrophy: An overview (2011) J Am Soc Hypertens, 4, pp. 319-324
dc.descriptionGaddam, K.K., Nishizaka, M.K., Pratt-Ubunama, M.N., Characterization of resistant hypertension: Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion (2008) Arch Intern Med, 168, pp. 1159-1164
dc.descriptionPimenta, E., Gaddam, K.K., Oparil, S., Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trial (2009) Hypertension, 54, pp. 475-481
dc.descriptionStruthers, A.D., MacDonald, T.M., Review of aldosterone- and angiotensin II-induced target organ damage and prevention (2004) Cardiovasc Res, 61, pp. 663-670
dc.descriptionPitt, B., Remme, W., Zannad, F., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction (2003) N Engl J Med, 348, pp. 1309-1321
dc.descriptionPitt, B., Zannad, F., Remme, W.J., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators (1999) N Engl J Med, 341, pp. 709-717
dc.descriptionEngbaek, M., Hjerrild, M., Hallas, J., The effect of low-dose spironolactone on resistant hypertension (2010) J Am Soc Hypertens, 4, pp. 290-294
dc.descriptionUeda, K., Okamura, N., Hirai, M., Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone (1992) J Biol Chem, 267, pp. 24248-24252
dc.descriptionUhr, M., Holsboer, F., Muller, M.B., Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins (2002) J Neuroendocrinol, 14, pp. 753-759
dc.descriptionBello-Reuss, E., Ernest, S., Holland, O.B., Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells (2000) Am J Physiol Cell Physiol, 278, pp. C1256-C1265
dc.descriptionFojo, A.T., Ueda, K., Slamon, D.J., Expression of a multidrug-resistance gene in human tumors and tissues (1987) Proc Natl Acad Sci U S A, 84, pp. 265-269
dc.descriptionMeissner, K., Sperker, B., Karsten, C., Expression and localization of P-glycoprotein in human heart: Effects of cardiomyopathy (2002) J Histochem Cytochem, 50, pp. 1351-1356
dc.descriptionThiebaut, F., Tsuruo, T., Hamada, H., Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues (1987) Proc Natl Acad Sci U S A, 84, pp. 7735-7738
dc.descriptionParker, R.B., Yates, C.R., Laizure, S.C., P-glycoprotein modulates aldosterone plasma disposition and tissue uptake (2006) J Cardiovasc Pharmacol, 47, pp. 55-59
dc.descriptionHoffmeyer, S., Burk, O., Von Richter, O., Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo (2000) Proc Natl Acad Sci U S A, 97, pp. 3473-3478
dc.descriptionKimchi-Sarfaty, C., Oh, J.M., Kim, I.W., A "silent" polymorphism in the MDR1 gene changes substrate specificity (2007) Science, 315, pp. 525-528
dc.descriptionMeissner, K., Jedlitschky, G., Zu, M., Schwabedissen, H., Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms (2004) Pharmacogenetics, 14, pp. 381-385
dc.descriptionWang, D., Johnson, A.D., Papp, A.C., Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability (2005) Pharmacogenet Genomics, 15, pp. 693-704
dc.descriptionSissung, T.M., Gardner, E.R., Piekarz, R.L., Impact of ABCB1 allelic variants on QTc interval prolongation (2011) Clin Cancer Res, 17, pp. 937-946
dc.descriptionBochud, M., Eap, C.B., Maillard, M., Association of ABCB1 genetic variants with renal function in Africans and in Caucasians (2008) BMC Med Genomics, 1, p. 21
dc.descriptionCascorbi, I., Paul, M., Kroemer, H.K., Pharmacogenomics of heart failure - Focus on drug disposition and action (2004) Cardiovasc Res, 64, pp. 32-39
dc.descriptionEap, C.B., Bochud, M., Elston, R.C., CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt (2007) Hypertension, 49, pp. 1007-1014
dc.descriptionVI Brazilian Guidelines on Hypertension [in Portuguese] (2010) Arq Bras Cardiol, 95, pp. 1-51
dc.descriptionTaylor, D.W., Sackett, D.L., Haynes, R.B., Compliance with antihypertensive drug therapy (1978) Ann N y Acad Sci, 304, pp. 390-403
dc.descriptionMorisky, D.E., Green, L.W., Levine, D.M., Concurrent and predictive validity of a self-reported measure of medication adherence (1986) Med Care, 24, pp. 67-74
dc.descriptionDe Souza, W.A., Yugar-Toledo, J.C., Bergsten-Mendes, G., Effect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertension (2007) Am J Health Syst Pharm, 64, pp. 1955-1961
dc.descriptionZolk, O., Jacobi, J., Pahl, A., MDR1 genotype-dependent regulation of the aldosterone system in humans (2007) Pharmacogenet Genomics, 17, pp. 137-144
dc.descriptionManunta, P., Ferrandi, M., Bianchi, G., Endogenous ouabain in cardiovascular function and disease (2009) J Hypertens, 27, pp. 9-18
dc.descriptionTripodi, G., Citterio, L., Kouznetsova, T., Steroid biosynthesis and renal excretion in human essential hypertension: Association with blood pressure and endogenous ouabain (2009) Am J Hypertens, 22, pp. 357-363
dc.descriptionFromm, M.F., Importance of P-glycoprotein at blood-tissue barriers (2004) Trends Pharmacol Sci, 25, pp. 423-429
dc.languageen
dc.publisherSAGE Publications Ltd
dc.relationJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
dc.rightsfechado
dc.sourceScopus
dc.titleMdr-1 C3435t Polymorphism May Affect Blood Pressure In Resistant Hypertensive Patients Independently Of Its Effects On Aldosterone Release
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución